New indication for Dupixent (dupilumab) as add on treatment for patients with severe asthma
EMA’s human medicines committee (CHMP) has recommended granting an extension of indication to Dupixent (dupilumab) as an add-on maintenance treatment for adult and adolescent (12 years and